trending Market Intelligence /marketintelligence/en/news-insights/trending/x53h6rjdirtzfc0cabgcrq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Oncology Venture nabs global rights to drug response prediction technology

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Oncology Venture nabs global rights to drug response prediction technology

Oncology Venture Sweden AB secured global exclusive development rights to Medical Prognosis Institute A/S' drug response prediction technology for a period of three years.

Oncology Venture will issue purchase warrants in exchange for the technology to develop new treatments. The warrants will be exercisable at 10 Swedish kronor for every share issued until Dec. 31, 2019.

Furthermore, Medical Prognosis will receive an ownership stake in Oncology Venture's special purpose vehicles instead of payments and earnings from the sale of the drugs developed by the technology.

As of Dec. 29, US$1 was equivalent to 9.12 Swedish kronor.